Figure 1
Institutional variability in the selection of first-line therapy for MCL patients (n = 167). Two institutions that contributed 4 patients to the study, 2 from each institution, are not included in the plot. All 4 patients received RHCVAD.
Institutional variability in the selection of first-line therapy for MCL patients (n = 167). Two institutions that contributed 4 patients to the study, 2 from each institution, are not included in the plot. All 4 patients received RHCVAD.
